Join to View Full Profile
1190 5th Ave# MountNew York, NY 10029
Phone+1 212-241-6756
Fax+1 212-423-0522
Dr. Aledort is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Rochester Medical CenterResidency, Internal Medicine, 1963 - 1964
University of Virginia Medical CenterResidency, Internal Medicine, 1959 - 1961
Albert Einstein College of MedicineClass of 1959
Certifications & Licensure
NY State Medical License 1963 - 2025
FL State Medical License 2016 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- Super Doctor SuperDoctors.com
Clinical Trials
- Cooperative Study of Factor VIII Inhibitors Start of enrollment: 1978 Jul 01
Publications & Presentations
PubMed
- 1 citationsChallenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals.Karin Berger, Roxy H O'Rourke, Matteo Nicola Dario Di Minno, Angelika Batorova, Kaan Kavakli
Haematologica. 2025-03-01 - 9 citationsNew directions to develop therapies for people with hemophilia.Pooja Gogia, Michael Tarantino, Wolfgang Schramm, Louis Aledort
Expert Review of Hematology. 2023-06-01 - Are all licensed haemostatic agents for haemophilia therapy accessible to patients?Karin Berger, Angelika Batorova, Rhonda Bohn, Matteo di Minno, Pier Mannuccio Mannucci
Haemophilia. 2022-11-01
Journal Articles
- Research Paper Application of Phospho-CyTOF to Characterize Immune Activation in Patients with Sickle Cell Disease in an Ex Vivo Model of ThrombosisLouis Aledort, MD, ScienceDirect
Press Mentions
Hemophilia Drug Hemlibra: Adverse Events Reports and Patient Deaths Raise Some ConcernsDecember 10th, 2019
Grant Support
- Safety And Clinical Efficacy Of Recombinant DNA Derived Factor VIIINational Center For Research Resources1993–1994
- Intranasal Ddavp Spray In Mild Hemophilia And Von Willebrand'S DiseaseNational Center For Research Resources1992
- Safety &Clinical Efficacy Of Recombinant DNA Derived Factor VIIINational Center For Research Resources1990–1992
- Recovery And Half-Life Studies Of Factor VII, VIII And IXNational Center For Research Resources1990–1991
- IVIG In Treatment Of Autoimmune &Alloimmune Antibodies To Coagulation FactorsNational Center For Research Resources1990–1991
- Immunoabsorption For Inhibitors To Factors VIII And IXNational Center For Research Resources1990
- Study Of IV Gamma Globulin For Treatment Of Autoimmune/Alloimmune AntibodiesNational Center For Research Resources1989
- Immunoabsorption For Inhibitors To Factors VIII And VNational Center For Research Resources1988–1989
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
